Exact Sciences Seeking Buyer or Merger Partner; Interim CEO Steps Down | GenomeWeb
NEW YORK (GenomeWeb News) – Oncology screening company Exact Sciences said it is seeking “strategic alternatives for the business,” which could include merging with or being bought by another company.
 
Marlborough, Mass.-based Exact, which has a license and marketing agreement with Laboratory Corporation of American for the sale of a colorectal cancer screening test, said today it has retained investment banking firm Leerink Swan to help it evaluate opportunities.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.